Real-World Efficacy Outcomes of FLT3-ITD^mut Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction

Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):154-157. doi: 10.1016/j.clml.2022.11.012. Epub 2022 Dec 5.

Authors

Itai Gueta¹, Victoria Marcu-Malina², Abraham Avigdor², Avichai Shimoni², Ronen Loebstein¹, Jonathan Canaani³

Affiliations

¹ Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Israel.
² Hematology Division, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Israel.
³ Hematology Division, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Israel. Electronic address: [email protected].

PMID: 36564312
DOI: 10.1016/j.clml.2022.11.012

No abstract available

Publication types

Letter

MeSH terms

Humans
Leukemia, Myeloid, Acute* / drug therapy
Mutation
Staurosporine / pharmacology
Staurosporine / therapeutic use
fms-Like Tyrosine Kinase 3 / genetics

Substances

midostaurin
Staurosporine
fms-Like Tyrosine Kinase 3
FLT3 protein, human